Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.

MLA

Levine, Monica D., et al. “Does the Choice of Platinum Doublet Matter? A Study to Evaluate the Impact of Platinum Doublet Choice for Treatment of Platinum-Sensitive Ovarian Cancer Recurrence on the Development of Future PARP Inhibitor and Platinum Resistance.” Gynecologic Oncology, vol. 182, Mar. 2024, pp. 51–56. EBSCOhost, https://doi.org/10.1016/j.ygyno.2023.12.008.

APA

Levine, M. D., Wang, H., Sriram, B., Khan, A., Senter, L., McLaughlin, E. M., Bixel, K. L., Chambers, L. M., Cohn, D. E., Copeland, L. J., Cosgrove, C. M., Nagel, C. I., O’Malley, D. M., & Backes, F. J. (2024). Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance. Gynecologic Oncology, 182, 51–56. https://doi.org/10.1016/j.ygyno.2023.12.008

Chicago

Levine, Monica D, Heather Wang, Bhargavi Sriram, Ambar Khan, Leigha Senter, Eric M McLaughlin, Kristin L Bixel, et al. 2024. “Does the Choice of Platinum Doublet Matter? A Study to Evaluate the Impact of Platinum Doublet Choice for Treatment of Platinum-Sensitive Ovarian Cancer Recurrence on the Development of Future PARP Inhibitor and Platinum Resistance.” Gynecologic Oncology 182 (March): 51–56. doi:10.1016/j.ygyno.2023.12.008.